March 2018

New Contraindications

Acarizax (house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae standardised allergen extract) is now contraindicated in patients with active or poorly controlled immune defects.

Burinex (bumetanide) is now contraindicated with hepatic encephalopathy.

Diane-35 ED, Juliet-35 ED (cyproterone acetate/ethinylestradiol), Qlaira (dienogest/estradiol valerate), Valette (dienogest/ethinylestradiol) and Yaz (drospirenone/ethinylestradiol) are now contraindicated with risk of venous thromboembolism (VTE), including known hereditary or acquired predisposition for VTE (such as activated protein C resistance (including factor V Leiden), antithrombin III deficiency, protein C or S deficiency), major surgery with prolonged immobilisation, or a high risk of VTE due to the presence of multiple risk factors. Diane-35 ED, Juliet-35 ED, Qlaira, Valette and Yaz are now also contraindicated with risk of arterial thromboembolism (ATE), including known hereditary or acquired predisposition for ATE (such as antiphospholipid antibodies (e.g. anticardiolipin, lupus anticoagulant) and hyperhomocysteinaemia), or a high risk of ATE due to multiple risk factors or to the presence of one serious risk factor such as severe hypertension or severe dyslipoproteinaemia.

Movapo PFS (apomorphine hydrochloride hemihydrate) is now contraindicated for children and adolescents under 18 years of age.

Nurofen Plus (ibuprofen/codeine phosphate hemihydrate) is now contraindicated with active or a history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severe hepatic impairment; concomitant treatment with monoamine oxidase inhibitors or within 14 days of stopping treatment; perioperative pain treatment in setting of coronary artery bypass surgery.

Renitec (enalapril maleate) is now contraindicated in combination with a neprilysin inhibitor (e.g. sacubitril). Do not administer Renitec within 36 hours of switching to or from sacubitril/valsartan, a product containing a neprilysin inhibitor.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au